Special Issue

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?

3 Dec 2020
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco

Precision immunotherapy is a crucial approach to improve the efficacy of anti-cancer treatments, particularly in the metastatic setting. In this respect, accurate patient selection takes advantage of the multidimensional integration of patients’ clinical information and tumour-specific biomarkers status. Among these biomarkers, programmed death-ligand 1, tumour-infiltrating lymphocytes, microsatellite instability, mismatch repair and tumour mutational burden have been widely investigated. However, novel tumour-specific biomarkers and testing methods will further improve patients’ outcomes. Here, we discuss the currently available strategies for the implementation of a precision immunotherapy approach in the clinical management of metastatic solid tumours and highlight future perspectives.

Related Articles

Joydeep Ghosh, Meheli Chatterjee, Sandip Ganguly, Anupurva Datta, Bivas Biswas, Geetashree Mukherjee, Sanjit Agarwal, Rosina Ahmed, Sanjoy Chatterjee, Deepak Dabkara
Ntokozo Ndlovu, Sandra Ndarukwa, Albert Nyamhunga, Patience Musiwa-Mba, Anna Mary Nyakabau, Webster Kadzatsa, Melinda Mushonga
Rebecca KS Wong, Verna Vanderpuye, Joel Yarne, Ntokozo Ndlovu, Nwamaka Lasebikan, Ewa Szumacher, Zahra Kassam